Navarro-Díaz Maruja, López-Martínez Marina
Genomic Platform, Germans Trias i Pujol's Research Insitute, 08916 Badalona, Spain.
Nephrology Department, Sant Joan Despí Moisès Broggi Hospital, 08970 Sant Joan Despí, Spain.
Biomedicines. 2025 Apr 24;13(5):1030. doi: 10.3390/biomedicines13051030.
Obesity increases the risk of cardiovascular disease, diabetes and chronic kidney disease. Obesity-related glomerulopathy (ORG) is a potentially reversible cause of kidney disease that often progresses silently until it reaches irreversible stages. However, we are still lacking a sensitive and specific biomarker to identify patients with obesity who are at risk of developing CKD. The role of microRNAs (miRNAs) has emerged as a promising area for diagnostic and therapeutic applications in kidney disease. Recent research has highlighted the specific roles of various miRNAs in renal function, showing that their dysregulation can contribute to the development of kidney diseases. This review will discuss the emerging role of miRNAs in the context of ORG, focusing on their potential as biomarkers and therapeutic targets for this increasingly prevalent disease.
肥胖会增加患心血管疾病、糖尿病和慢性肾脏病的风险。肥胖相关肾小球病(ORG)是一种潜在可逆的肾脏疾病病因,通常会在不知不觉中进展,直至发展到不可逆阶段。然而,我们仍缺乏一种敏感且特异的生物标志物来识别有患慢性肾脏病风险的肥胖患者。微小RNA(miRNA)的作用已成为肾脏病诊断和治疗应用中一个很有前景的领域。最近的研究突出了各种miRNA在肾功能中的特定作用,表明它们的失调会促使肾脏疾病的发生。本综述将讨论miRNA在ORG背景下的新作用,重点关注其作为这种日益普遍疾病的生物标志物和治疗靶点的潜力。